Supriya Lifescience Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company also reported the appointment of Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel, effective from November 6, 2026. The results and appointment were approved by the Board of Directors on November 6, 2026.
Supriya Lifescience Announces Q2 FY27 Financials and Key Appointment
On November 6, 2026, Supriya Lifescience Limited held a Board Meeting where it considered and approved its unaudited financial results for the quarter and half-year ended September 30, 2026. The accompanying Limited Review Report from the Statutory Auditors has also been finalized.
New Chief Operating Officer Appointed
Following a recommendation from the Nomination and Remuneration Committee, the Board of Directors approved the appointment of Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel. This appointment is effective from November 6, 2026. Mr. Vaze brings approximately 34 years of professional experience in areas such as Production, Process Engineering, and API Manufacturing, having previously worked with companies like Zydus Lifescience, Cipla, and Wockhardt.
Financial Highlights
The standalone financial results for the quarter ended September 30, 2026, show a profit of ₹292.50 million. For the half-year ended September 30, 2026, the profit stood at ₹532.93 million. Revenue from operations for the quarter was ₹2,062.97 million, and for the half-year, it was ₹3,960.44 million.
Other Information
The company also stated that information pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, is enclosed. The full financial results and related information will be available on the company’s website.
Source: BSE
